These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 26139104)
1. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. Upreti VV; Wahlstrom JL J Clin Pharmacol; 2016 Mar; 56(3):266-83. PubMed ID: 26139104 [TBL] [Abstract][Full Text] [Related]
2. Development and Evaluation of Ontogeny Functions of the Major UDP-Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations. Farhan N; Dahal UP; Wahlstrom J J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38898531 [TBL] [Abstract][Full Text] [Related]
3. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo. Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511 [TBL] [Abstract][Full Text] [Related]
4. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods? Björkman S Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308 [TBL] [Abstract][Full Text] [Related]
5. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study. Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268 [TBL] [Abstract][Full Text] [Related]
6. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. Yun YE; Edginton AN J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354 [TBL] [Abstract][Full Text] [Related]
7. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476 [TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 enzymes in the pediatric population: Connecting knowledge on P450 expression with pediatric pharmacokinetics. Emoto C; Johnson TN Adv Pharmacol; 2022; 95():365-391. PubMed ID: 35953161 [TBL] [Abstract][Full Text] [Related]
9. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Leong R; Vieira ML; Zhao P; Mulugeta Y; Lee CS; Huang SM; Burckart GJ Clin Pharmacol Ther; 2012 May; 91(5):926-31. PubMed ID: 22472993 [TBL] [Abstract][Full Text] [Related]
10. Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children. Cleary Y; Kletzl H; Grimsey P; Heinig K; Ogungbenro K; Silber Baumann HE; Frey N; Aarons L; Galetin A; Gertz M Clin Pharmacokinet; 2023 Jun; 62(6):891-904. PubMed ID: 37148485 [TBL] [Abstract][Full Text] [Related]
11. A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. Dallmann A; Ince I; Coboeken K; Eissing T; Hempel G Clin Pharmacokinet; 2018 Jun; 57(6):749-768. PubMed ID: 28924743 [TBL] [Abstract][Full Text] [Related]
12. Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Shida S; Utoh M; Murayama N; Shimizu M; Uno Y; Yamazaki H Xenobiotica; 2015; 45(10):881-6. PubMed ID: 26075833 [TBL] [Abstract][Full Text] [Related]
13. The use of PBPK modeling across the pediatric age range using propofol as a case. Michelet R; Van Bocxlaer J; Allegaert K; Vermeulen A J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):765-785. PubMed ID: 30298439 [TBL] [Abstract][Full Text] [Related]
14. Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants. Malik PRV; Edginton AN J Clin Pharmacol; 2020 Apr; 60(4):466-476. PubMed ID: 31729044 [TBL] [Abstract][Full Text] [Related]
15. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. Salem F; Johnson TN; Barter ZE; Leeder JS; Rostami-Hodjegan A J Clin Pharmacol; 2013 Aug; 53(8):857-65. PubMed ID: 23720017 [TBL] [Abstract][Full Text] [Related]
16. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Alcorn J; McNamara PJ Clin Pharmacokinet; 2002; 41(13):1077-94. PubMed ID: 12403644 [TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients. Heimbach T; Lin W; Hourcade-Potelleret F; Tian X; Combes FP; Horvath N; He H J Pharm Sci; 2019 Jun; 108(6):2191-2198. PubMed ID: 30721710 [TBL] [Abstract][Full Text] [Related]